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This study aimed to compare the prevalence of 25-hydroxy vitamin 
D deficiency in cerebral palsied (CP) with healthy control children and 
evaluate possible correlations between serum level of 25-hydroxy vitamin 
D and severity of CP and motor function. 
Materials & Methods
In this case-control study, serum levels of 25-hydroxy vitamin D were 
evaluated in 65 children with CP and compared with 65 healthy children 
referred to Tabriz Pediatric Hospital, Tabriz, northwestern Iran in 2015. 
Blood samples were taken to measure levels of 25-hydroxy vitamin D, 
calcium, phosphorus and alkaline phosphatase. Regarding 25-hydroxy 
vitamin D levels, patients were classified as sufficient (≥30 ng/ml), 
insufficient (20-30 ng/ml) and deficient (<20 ng/ml). 
Results
Mean 25-hydroxy vitamin D levels were 28.03±24.2 ng/ml in patients and 
30±1.94 ng/ml in control group. 25-hydroxy vitamin D deficiency was seen 
in 44.6% of CP and 18.5% of healthy children. There was no significant 
difference in 25-hydroxy vitamin D levels between boys and girls, CP types 
and use of antiepileptics in case group. There was significant negative 
correlation between age and 25-hydroxy vitamin D levels (P=0.007). The 
correlation between 25-hydroxy vitamin D and Gross Motor Function 
Classification System was not significant. 
Conclusion
25-hydroxy vitamin D deficiency is common in children with CP in 
comparison with healthy children. There was significant negative correlation 
between age and 25-hydroxy vitamin D levels. Routine measurement of 
25-hydroxy vitamin D levels and its proper treatment is recommended to 
prevent its deficiency and subsequent consequences.




Cerebral palsy (CP) is the most common developmental disabilities in childhood 
which persist throughout the lifespan, is a clinical syndrome characterized by a 
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Materials & Methods 
In this case-control study, 25-hydroxy vitamin D status 
of 65 children with CP visiting outpatient clinics of 
Tabriz Pediatric Hospital, Tabriz, northwestern Iran 
in 2015 was evaluated and compared with healthy 
age and sex-matched children without history of 
chronic disease. Considering 95% confidence, power 
of 80% and according to the similar studies d=3.76, 
s1=8.75 and s2=6.24 we determined the sample size 
of 65 participants for each study group. Inclusion 
criteria were children of both sexes between 3-11 yr 
old with confirmed CP for case group and without 
any chronic disease for control group and no history 
of 25-hydroxy vitamin D or calcium supplement use 
in recent 2 months.
Ethics Committee of Tabriz University of Medical 
Sciences approved the study, and the written 
informed consent was obtained from the parents or 
legal guardians of children.
Demographic findings, history of supplement use, 
anti-epileptic medications use and Gross Motor 
Function Classification System (GMFCS) were 
recorded. Calcium, phosphorus, alkaline phosphatase 
and 25-hydroxy vitamin D levels were measured. 
A peripheral non-fasting venous blood sample was 
obtained for analysis of multiple factors relating to 
nutrition or bone metabolism. The hospital laboratory 
at the respective institutions determined serum levels 
of calcium, phosphate, alkaline phosphatase using 
Pars Azmoon DGKC spectrophotometry kits in case 
group. Serum 25-hydroxy vitamin D was measured 
in the Sheikh Al-Rais Laboratory using ELISA 
Diasource kits (Louvain-la-Neuve, Belgium) in 
both study groups. All evaluations were done in 
the same season (spring and summer). The values 
for 25-hydroxy vitamin D levels ≥30 ng/ml were 
considered as sufficient, between 20 and 30 ng/ml as 
insufficient and <20 ng/ml as deficient (12).
persistent disorder in motor control and posture, and 
results from injury or dysfunction of the brain which 
is non-progressive (1, 2). The motor disorders of 
cerebral palsy are often accompanied by disturbances 
of sensation, cognition, communication and behavior, 
epilepsy, and secondary musculoskeletal problems (3, 
4). Children with CP experience limitations in their 
daily activities e.g. feeding, dressing, bathing, and 
mobility due to abnormal muscle tone, involuntary 
movement, unsteady gait, problems with balance, 
and poor social functioning (5, 6). They have also 
difficulties in swallowing. Feeding difficulty and 
malnutrition are two of the associated problems 
in cerebral palsy (7). These patients usually have 
poor overall nutrition and insufficient calcium and 
25-hydroxy vitamin D intake (8).
In childhood, 25-hydroxy vitamin D is crucial for 
bone growth, mineralization, and musculoskeletal 
health because it promotes the assimilation of 
nutritional calcium and phosphate. It also regulated 
numerous cellular functions and would play an 
important role in the risk of metabolic syndrome, 
diabetes, autoimmune diseases, and some types of 
cancer (9). “Severe 25-hydroxy vitamin D deficiency 
(VDD) can result in rickets, metabolic bone disease, 
and hypocalcemia during infant and childhood 
growth” (10).
Because of nutritional deficiency, lack of sun 
exposure and sedentary behavior, osteopenia and 
rickets are common in children with CP. Patients 
have significantly decreased bone mineral density. 
In addition, painful fractures with minor traumas are 
common (11). 
In this study, we aimed to assess prevalence of 
25-hydroxy vitamin D deficiency in children with 
CP and possible correlations between 25-hydroxy 
vitamin D and severity of CP and motor function was 
evaluated. 
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5/4/2767 and ethical code of this study was 91/1-
7/16. The measurement of serum levels of vitamin 
D  were paid  by the Research Center of Physical 
Medicine and Rehabilitation.
Results
Sixty-five children with CP were evaluated for 
25-hydroxy vitamin D and compared with 65 
healthy children. Table 1 demonstrates demographic 
and laboratory findings between groups. There was 
no significant difference in age or gender between 
groups. 44.6% of cerebral palsied and 18.5% of 
control children had deficient levels of 25-hydroxy 
vitamin D, including 9 patients (13.8%) with severe 
deficiency (25-hydroxy vitamin D levels <10 ng/
ml) in case group. Using post-hoc analysis showed 
that children with CP compared to normal group 
had significantly higher rate of vitamin D deficiency 
(P=0.008). Correlation between 25-hydroxy vitamin 
D and age was evaluated and there was significantly 
negative correlation between 25-hydroxy vitamin D 
and age (P=0.007). Using Two-way ANOVA, there 
was not a significant interaction between the effects 
of gender and groups on 25-hydroxy vitamin D 
levels (Table 1). Although main effect analysis did 
not show statistically significant differences, boy’s 
25-hydroxy vitamin D levels were considerably 
higher in case group. 
GMFCS 
GMFCS is a standard observational tool for assessing 
children with cerebral palsy that evaluated the ability 
to perform movements such as walking, climbing 
stairs, running and sitting. According to this scale, 
children are placed into five grades from I to V in 
order to their gross motor skills and lower levels 
represent better gross motor skills, with I as the 
lightest and V as the most severe level (13). 
Statistical Analysis 
All statistical tests were performed using SPSS for 
Windows Ver. 17 (Chicago, IL, USA). Quantitative 
data were presented as mean ± standard of error 
(S.E), while qualitative data were demonstrated as 
frequencies and percentages (percentage). After 
determining of frequency distribution of variables 
using Kolmogorov-Smirnov test, independent t-test, 
one-way and two-way ANOVA, chi-square test or 
Fisher’s exact tests and Pearson correlation test, 
as appropriate were used to compare data between 
groups of patients. Pearson correlation was used to 
evaluate the correlation between variables. A P-value 
of <0.05 was considered statistically significant. 
This study was approved by the Ethics Committee of 
Tabriz University of Medical Sciences and informed 
consents were obtained from all study participants. 
The registry number of confirmation letter was 
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serum levels of phosphorus. 
We found no significant difference between boys and 
girls, CP types and use of antiepileptics regarding 
25-hydroxy vitamin D levels (Table 2). Correlation 
between 25-hydroxy vitamin D with GMFCS level, 
age, and laboratory findings was evaluated and there 
was only significantly negative correlation between 
25-hydroxy vitamin D and age (r=-0.333, P=0.007). 
Discussion
We evaluated the 25-hydroxy vitamin D levels in 
Patients were mostly spastic (73.8%) and 
quadriplegic type (43.1%). Antiepileptic medication 
was positive in 19 patients in case group (with 
phenobarbital). Most patients had GMFCS level 
II and III. The result from exact test indicated that 
prevalence of 25-hydroxy vitamin D Deficiency was 
the same between GMFC categories (GMFCI- II- III 
vs. IV-V). Lower calcium levels (<8.5 µg/dL) were 
observed only in one patient (15%). Elevated levels 
of alkaline phosphatase and high serum phosphorus 
(>4.5 µg/dL) were observed in 29 (44.61%) and 22 
(33.84%), respectively. None of the cases had lower 
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Age (yr) 5.9±0.30 6.23±0.37 0.523*
Gender
Boys 37 (56.9) 38(58.5)
0.859**
Girls 28 (43.1) 27(41.55)





Toxicity 1 (1.5) 1(1.5)










25-hydroxy vitamin D levels
Control(n=65)
Mean ± S.E*
25-hydroxy vitamin D levels
Boys 30.69 ± 3.36 29.45 ± 3.31
0.506 †
Girls 24.52 ± 3.86 30.78 ± 3.93
P-value 0.491† 0.303 †
* Standard of Error         *** Pearson Correlation Test            * Independent-Samples t-test          † Two-Way Anova
** Pearson Chi-Square Test                                                      ‡ Level of significance is considered to be <0.05
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cerebral palsied and healthy children and observed 
higher rate of 25-hydroxy vitamin D deficiency 
(44.6%) and severe deficiency (13.8%) in CP cases. 
There is different reported prevalence of 25-hydroxy 
vitamin D deficiency around the world varying 
from 40% to 52.4% (14, 15). Among Iranian normal 
school-aged children and adolescents, two studies 
have reported high prevalence rate (16, 17). Children 
with CP have higher rate of 25-hydroxy vitamin D 
deficiency compared to normal children. However, 
in our study, it was similar to studies in other 
countries (14,15). The higher rate of 25-hydroxy 
vitamin D deficiency among children is suggested 
to be related to insufficient sun exposure, low 
physical activity, advancing age and pubertal stage 
(14-17). Recommended mechanisms among children 
with CP are poor nutritional status, oral motor 
dysfunction, feeding problems, insufficient calcium 
intake, non-ambulatory status, and anticonvulsant 
use (18). Antiepileptic drugs are associated with 
reduced 25-hydroxy vitamin D levels, rickets, 
and osteomalacia (19, 20). Anti-epileptic drugs, 
especially enzyme-inducing ones, may result in 
accelerated vitamin D metabolism and so vitamin D 
levels are decreased and consequently result in bone 
mineral density reduction (21). However, we found no 
significant difference regarding 25-hydroxy vitamin 
D levels in children treated or not with antiepileptics. 
Due to the small sample of the study and patients in 
the groups with and without antiepileptic drug use, 
these results should be interpreted with caution. 
25-hydroxy vitamin D insufficiency is more prevalent 
among girls (22). 25-hydroxy vitamin D deficiency 
is higher in girls than boys in normal population are 
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Table 2. 25-hydroxy vitamin D levels between CP types, GMFCS groups, and Antiepileptic usage status
Variable Categories n (%)
 Mean ± S.E
25-hydroxy vitamin D levels
P-value
Type of CP, n (%)
Hemiplegic 14 (21.5) 21.34 ± 5.29
0.220**Quadriplegic 28 (43.1) 35.02 ± 5.90
Diplegic 23 (35.1) 23.60 ± 2.70
Type of CP, n (%)
Spastic 48 (73.8) 24.84 ± 2.70
0.389**
Hypotonic 10 (15.4) 36.42 ± 6.76
Dyskinetic 2 (3.1) 25.12 ± 3.38
Mixed 5 (7.7) 43.08 ± 27.06
GMFCS, n (%)
I,II,III 56 (86.2) 28.61± 24.09
IV,V 9 (13.8) 24.33 ± 20.87 0.174**
Antiepileptic use
Yes 19 (29.2) 26.78 ± 4.11
0.791***




Deficient Insufficient Sufficient Toxicity
I- II- III 24 (42.85) 14 (25%) 17 (30.35) 1 (1.7)
0.664†
IV- V 5 (55.55) 1 (11.11%) 3 (33.33) 0 (0)
* Standard of Error.     † Exact Test.       ** Kruskal Wallis Test.    ‡ Level of significance is considered to be <0.05. 
*** Independent-Samples t-test.
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(15). However, in this study, although girls had lower 
25-hydroxy vitamin D levels, the difference between 
boys and girls was not significant. In our region, the 
girls are dressed as most parts are covered and so 
have less sun exposure, which could be a cause for 
this finding. 
We also found that with increase in the subjects’ age, 
the 25-hydroxy vitamin D levels are reduced and 
are more prone to 25-hydroxy vitamin D deficiency. 
Similarly, the frequency of 25-hydroxy vitamin D 
deficiency was increased with age (15). Lower outdoor 
activity and consequently lower sun exposure are 
regarded as one of the causes for higher 25-hydroxy 
vitamin D deficiency rate in older age (23). 
We also found no correlation between significant 
difference in 25-hydroxy vitamin D levels among 
spastic, dyskinetic, mixed and hypotonic CP as well 
as quadriplegic, hemiplegic and diplegic types. In 
addition, there was no significant difference between 
GMFCS level and 25-hydroxy vitamin D levels. 
GMFCS was not associated with 25-hydroxy vitamin 
D levels (8). However, children in GMFCS level I 
to II have less severe bone deficits than children in 
GMFCS level III to IV (24). Most cases in our study 
were in GMFCS level II and III and levels I, IV and 
V constituted only 12 cases, which may be reason for 
not finding significant association. 
Some limitation of our study should be considered 
as follows: The large sample for GMFCS II and III 
was the main cause limited our analysis. The data 
with regard to degree of sun exposure could not be 
objectively assessed. The study was done on small 
sample of patients and in an area with different 
climates and cultures. 
In conclusion, prevalence of 25-hydroxy vitamin 
D deficiency was higher in this study population 
in comparison with healthy control children. There 
was significant negative correlation between age and 
25-hydroxy vitamin D levels Routine measurement 
of 25-hydroxy vitamin D levels and proper treatment 
if needed, is recommended to prevent 25-hydroxy 
vitamin D deficiency and subsequent consequences. 
Future research should focus on the benefits of 
25-hydroxy vitamin D supplementation for this 
population.
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